Skip to content

Stiripentol (diacomit(R)) for refractory epilepsy patients with autoimmune encephalitis

Stiripentol (diacomit(R)) for refractory epilepsy patients with autoimmune encephalitis - Stiripentol (diacomit(R)) for refractory epilepsy patients with autoimmune encephalitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023741
Enrollment
6
Registered
2016-08-25
Start date
2016-08-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory epilepsy

Interventions

stiripentol 1000mg per day, oral twice-daily dosage at first medication dose up 500mg per day every week if no adverse effect, dose up until seizure is free, or up to 2500mg maximum dose per day

Sponsors

Nagoya City University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: autoimmune encephalitis is diagnosed in adult cases uncontrolled seizures are prolonged even treated with useful multiple antiepileptic drugs(AEDs), or no other AEDs can be medicated on account of drug allergy.

Exclusion criteria

Exclusion criteria: patients allergic to component of this drug pregnant or possibly pregnant women patients chief or sub investigator diagnose inappropriate

Design outcomes

Primary

MeasureTime frame
neurological sign: continuous observation about presence or absence, frequency, and duration of seizures after medication

Secondary

MeasureTime frame
electroencephalogram(EEG): continuous observation about presence or absence of epileptic discharges in simple EEG fitted all the time, and 10-20 EEG at every two weeks after medication

Countries

Japan

Contacts

Public ContactKenji Okita

Nagoya City University Department of Neurology

neuron4356@yahoo.co.jp052-853-8094

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026